Companies Addressing Unmet Medical Needs
Today, Axsome Therapeutics announced that the first patient has been dosed with AXS-12 for Narcolepsy in the phase 3 clinical trial known as SYMPHONY. The expected completion, and readout of this clinical trail, will be in the first half of 2023.
No comments:
Post a Comment